Authorities in Bengaluru are investigating a suspected counterfeit medicine network allegedly supplying spurious, relabelled and repackaged drugs to more than 90 hospitals and clinics. The probe began after the Karnataka Food Safety and Drug Administration seized medicines and equipment worth around ₹4.91 crore from an unauthorised facility near Bidadi on August 18.
Investigators allege that lower-cost or expired medicines were repackaged and sold under labels resembling those of reputed pharmaceutical companies, with some suspected products linked to cancer treatment and critical-care use.
The Karnataka Government subsequently formed a six-member Special Investigation Team (SIT), headed by Bengaluru Joint Commissioner of Police (West) C Vamshikrishna. The investigation has now widened beyond Karnataka, with coordinated searches reported across more than 10 locations in six states.
Police have arrested Bengaluru pharmacist and Krupa Healthcare owner Veeresh Kumar Jain, while another alleged key accused, identified as Prashant, remains absconding. SIT chief C Vamshikrishna said investigators are examining bank records, purchase and sale vouchers and other documents to trace the movement of medicines and money and determine the full extent of the suspected interstate network.
Health Minister U T Khader had earlier described the case as potentially a “national” or “international and interstate” racket, saying the suspected medicines were allegedly sourced from other states and relabelled before being supplied to shops and hospitals.
₹5 Crore Seizure Raises Alarm
The case came to light when the Drug Enforcement Wing of Karnataka’s Food Safety and Drug Administration raided an alleged unauthorised pharmaceutical repacking facility at a farmhouse near Bidadi in Bengaluru South.
Officials seized suspected spurious medicines and related material valued at approximately ₹4.91 crore, including thousands of injectable medicines, expired stock, packaging material, counterfeit labels and injection-filling equipment.
Investigators allege that cheaper medicines procured from other states were transferred into new vials and relabelled to resemble expensive branded or imported products. Samples were sent for laboratory testing to establish their chemical composition, sterility and potency, meaning the exact nature of the seized products is yet to be conclusively established.
Khader said the drugs were allegedly sourced from places including Himachal Pradesh and Telangana before being relabelled and supplied to shops and hospitals. “If one day we get almost Rs 5 crore worth of fake drugs, I wonder how many crores worth of fake drugs are already among people,” the minister was quoted as saying, while stressing that the probe would examine suppliers, logistics operators, agents, middlemen, hospitals and pharmacies.
The seizure included products allegedly bearing names associated with major pharmaceutical companies, intensifying concerns over how counterfeit medicines could enter legitimate-looking healthcare channels.
Probe Expands Across States
The investigation has since moved beyond the Bidadi facility. The SIT and Drugs Control Department reportedly traced part of the suspected supply chain to Krupa Healthcare near Minerva Circle in Bengaluru, where officers seized suspected counterfeit medicines along with financial and distribution records.
Its proprietor, Veeresh Kumar Jain, has been arrested over allegations that the pharmacy was used as a storage and distribution point. Investigators suspect that the network supplied cancer medicines, life-saving drugs and ICU injections to more than 90 hospitals and clinics, allegedly offering some products at discounts of around 50%.
Police are also examining the role of more than 15 medical representatives who allegedly helped move or market the medicines. The latest development came with simultaneous searches at more than 10 locations across six states, including Karnataka, Haryana, Himachal Pradesh, Tamil Nadu and Maharashtra, as investigators work to identify suppliers, distributors, destinations and the value of transactions.
Vamshikrishna said the police were still trying to establish the full extent of the interstate network and were collating bank transaction records, purchase and sale vouchers and other documents to map the flow of medicines and money.
Pharmacists have also raised questions about the alleged route, noting that many of the seized products are specialised critical-care medicines generally not stocked by conventional retail chemists. They suggested investigators examine hospital pharmacies, intermediaries and online sellers.
Importantly, the involvement of more than 90 hospitals does not mean those establishments knowingly bought or administered counterfeit medicines; investigators are still determining where the products went and whether any patients received them.
Experts Call For Stronger Drug Checks
Experts say hospitals and pharmacies need stronger medicine-verification systems, especially for high-value cancer and critical-care drugs. Procurement teams should verify manufacturers, batch numbers, invoices, licences and supply-chain records before accepting medicines, while digital tracking can help identify suspicious products as they move between suppliers and healthcare facilities.
They also stress the need for regular audits, tighter checks on distributors and prompt reporting of suspected counterfeit medicines to regulators. For patients, experts advise buying medicines only through authorised channels and checking packaging, batch details and expiry dates, while avoiding unusually discounted products without verified documentation.
The Logical Indian’s Perspective
The Bengaluru investigation is a reminder that medicines are not ordinary commercial products: for a patient battling cancer or fighting for survival in an ICU, the authenticity, quality and safety of a drug can literally determine the outcome of treatment. If the allegations are proven, those who deliberately exploit vulnerable patients and healthcare institutions for profit must face strict legal action. At the same time, the investigation must remain evidence-led and fair.
Hospitals, pharmacists, medical representatives and other businesses should not be publicly blamed merely because their names or transactions appear in records; responsibility must be established through evidence. The focus should now be on tracing every suspected batch, strengthening procurement and verification systems, improving supply-chain transparency and ensuring that patients are protected without creating unnecessary panic.
Also read: BRICS 2026: Can India Become a Manufacturing Alternative to China for the Global South?
